Bank of New York Mellon’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.16M | Buy |
121,166
+6,631
| +6% | +$63.6K | ﹤0.01% | 3043 |
|
|
2025
Q1 | $718K | Buy |
114,535
+11,787
| +11% | +$73.9K | ﹤0.01% | 3236 |
|
|
2024
Q4 | $834K | Buy |
102,748
+4,557
| +5% | +$37K | ﹤0.01% | 3245 |
|
|
2024
Q3 | $1.78M | Sell |
98,191
-16,530
| -14% | -$299K | ﹤0.01% | 2810 |
|
|
2024
Q2 | $1.18M | Buy |
114,721
+19,500
| +20% | +$201K | ﹤0.01% | 3096 |
|
|
2024
Q1 | $1.01M | Sell |
95,221
-11,098
| -10% | -$118K | ﹤0.01% | 3136 |
|
|
2023
Q4 | $971K | Buy |
106,319
+11,254
| +12% | +$103K | ﹤0.01% | 3199 |
|
|
2023
Q3 | $986K | Buy |
95,065
+16,478
| +21% | +$171K | ﹤0.01% | 3152 |
|
|
2023
Q2 | $1.13M | Buy |
78,587
+1,250
| +2% | +$17.9K | ﹤0.01% | 3121 |
|
|
2023
Q1 | $552K | Sell |
77,337
-2,598
| -3% | -$18.6K | ﹤0.01% | 3442 |
|
|
2022
Q4 | $897K | Buy |
79,935
+6,415
| +9% | +$72K | ﹤0.01% | 3246 |
|
|
2022
Q3 | $814K | Buy |
73,520
+9,163
| +14% | +$101K | ﹤0.01% | 3304 |
|
|
2022
Q2 | $544K | Buy |
64,357
+3,069
| +5% | +$25.9K | ﹤0.01% | 3537 |
|
|
2022
Q1 | $834K | Buy |
61,288
+1,948
| +3% | +$26.5K | ﹤0.01% | 3419 |
|
|
2021
Q4 | $1.17M | Buy |
59,340
+1,198
| +2% | +$23.6K | ﹤0.01% | 3291 |
|
|
2021
Q3 | $1.87M | Buy |
58,142
+7,323
| +14% | +$235K | ﹤0.01% | 3016 |
|
|
2021
Q2 | $1.72M | Buy |
50,819
+9,597
| +23% | +$325K | ﹤0.01% | 3094 |
|
|
2021
Q1 | $1.55M | Sell |
41,222
-2,446
| -6% | -$91.9K | ﹤0.01% | 3070 |
|
|
2020
Q4 | $1.45M | Sell |
43,668
-264
| -0.6% | -$8.77K | ﹤0.01% | 3026 |
|
|
2020
Q3 | $1.61M | Sell |
43,932
-183
| -0.4% | -$6.71K | ﹤0.01% | 2794 |
|
|
2020
Q2 | $1.45M | Buy |
44,115
+5,882
| +15% | +$194K | ﹤0.01% | 2874 |
|
|
2020
Q1 | $987K | Buy |
38,233
+13,439
| +54% | +$347K | ﹤0.01% | 2990 |
|
|
2019
Q4 | $772K | Buy |
+24,794
| New | +$772K | ﹤0.01% | 3358 |
|